Efficacy and Safety of Icotinib in the Treatment of Advanced Non-small Cell Lung Cancer ：a Meta-analysis
- VernacularTitle:埃克替尼治疗晚期非小细胞肺癌有效性与安全性的Meta分析
- Author:
Wei LIN
1
;
Meixia LI
2
;
Wei LU
1
;
Chengde WU
1
;
Ximiao MA
1
;
Li LI
1
;
Fangyong FU
1
Author Information
1. First Dept. of Cardio-thoracic Surgery，the Affiliated Haikou Hospital of Xiangya Medical College，Central South University，Haikou 570208，China
2. Dept. of Anesthesiology，the Affiliated Haikou Hospital of Xiangya Medical College，Central South University，Haikou 570208，China
- Publication Type:Journal Article
- Keywords:
Icotinib;
Advanced non-small cell lung cancer;
Efficacy;
Safety;
Meta-analysis
- From:
China Pharmacy
2019;30(4):533-537
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE： To evaluate the efficacy and safety of icotinib in the treatment of advanced non-small cell lung cancer （NSCLC）， and to provide evidence-based reference for clinical drug use. METHODS： Retrieved from the Cochrane library， PubMed， Sciencedirect， CNKI， Wanfang database and VIP， RCTs about icotinib or icotinib combined with routine treatment or with other drugs （trial group） versus routine treatment or other drugs （control group） in the treatment of advanced NSCLC were collected. After literature screening， data extraction and literature quality evaluation with Cochrane collaboration bias risk assessment tool 5.1.0， Meta-analysis was performed by using Rev man 5.3 statistical software. RESULTS： A total of 27 RCTs were included， involving 2 345 patients. Results of Meta-analysis showed that response rate [OR＝1.64， 95％CI（1.36， 1.97）， P＜0.000 01] and disease control rate [OR＝1.68， 95％CI（1.39， 2.04）， P＜0.000 01] in trial group were significantly higher than control group； the incidence of ADR in trial group [OR＝0.59， 95％CI（0.48， 0.72）， P＜0.000 01] was significantly lower than control group. CONCLUSIONS： Icotinib shows good efficacy and safety in the treatment of advanced NSCLC.
